A
Abcuro
Biotech & Life Sciences · Newton, United States · Founded 2015
The next generation of T cell targeted bio-therapeutics MoreLess
Abcuro, Inc. is a biotechnology company focused on developing advanced immunotherapies to treat autoimmune diseases and cancer. The company operates in the biopharmaceutical market, specifically targeting dysfunctional immune pathways to create novel therapies. Abcuro takes a patient-centric approach, identifying and validating the role of these pathways in various diseases to discover new treatments. The company primarily serves patients suffering from autoimmune conditions and certain types of cancer. Abcuro's business model revolves around research and development, with revenue generated through partnerships, grants, and potential future sales of their proprietary therapies. The company is headquartered in Newton, MA, and is led by a team of experienced scientists and medical professionals. Key areas of focus include the role of KLRG1 T cells in diseases like Primary Biliary Cholangitis and Inclusion Body Myositis.
Keywords: immunotherapies, T cells, autoimmunity, cancer, biotechnology, patient-centric, immune pathways, biopharmaceutical, KLRG1, research and development.
Company overview
Abcuro company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2015
- Headquarters
- Newton, United States
- Employees
- 40
- Open positions
- None listed
- Dealroom signal
- 65.3
Valuation & funding
Abcuro funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Feb 2025 | $200M | $800M | Redmile Group · RA Capital Management · Samsara BioCapital · Bain Capital Life Sciences | ↗ |
| SERIES BOther financing | Aug 2023 | $155M | $620M | Tekla Capital Management · Pontifax Funds · Redmile Group · Samsara BioCapital | ↗ |
| SERIES AOther financing | Jan 2021 | $42M | $168M | RA Capital Management · Samsara BioCapital · Sanofi Ventures | — |
| EARLY VCOther financing | Nov 2018 | $8M | $32M | Undisclosed | — |
| SEEDOther financing | Dec 2016 | $2.3M | $9.2M | Undisclosed | — |
| SPINOUTOther financing | Jan 2015 | Brigham and Women's Hospital · Harvard Medical School | — |
Growth signals
Abcuro website traffic
Latest recorded traffic for Abcuro is 2.5K monthly website visits, down 21.9% over the last three months. Abcuro's team declined 27.3% over the past year.
Comparisons
Abcuro compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Abcuro's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Abcuro has talent and traffic
team presence
In the news
Latest news about Abcuro
Recent press, funding announcements, and product moves mentioning Abcuro — open to read from the original sources.
Market sentiment
What the market is saying about Abcuro
An AI-synthesized read of the highest-engagement posts about Abcuro on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Abcuro’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.